AbCellera Biologics (ABCL) EBT (2020 - 2026)
AbCellera Biologics (ABCL) posted EBT of -$49.5 million for Q1 2026, down 154.05% on a QoQ basis from -$19.5 million in Q4 2025, and up 6.51% year-over-year from -$46.5 million in Q1 2025.
AbCellera Biologics (ABCL) EBT (2020 - 2026) Analysis & Trends
AbCellera Biologics' EBT history runs 7 years deep, the most recent figure standing at -$49.5 million for Q1 2026.
- Quarterly EBT rose 6.51% year-over-year to -$49.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.1 million (up 17.32% YoY) and the FY2025 annual result came in at -$177.6 million, up 11.38% from the prior year.
- EBT was -$49.5 million for Q1 2026 at AbCellera Biologics, down from -$19.5 million in the prior quarter.
- Across five years, EBT topped out at $230.8 million in Q1 2022 and bottomed at -$68.8 million in Q3 2025.
- A 5-year average of -$21.3 million and a median of -$42.7 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT jumped 286.56% — and 2023, when it tumbled 451.9%.
- AbCellera Biologics' EBT stood at -$31.4 million in 2022, then plunged by 54.72% to -$48.6 million in 2023, then advanced by 3.65% to -$46.8 million in 2024, then surged by 58.36% to -$19.5 million in 2025, then plunged by 154.05% to -$49.5 million in 2026.
- Business Quant data shows ABCL's EBT at -$49.5 million in Q1 2026, -$19.5 million in Q4 2025, and -$68.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | AbCellera Biologics | 1.62 Bn | 1.62 Bn | - | -49.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.54 Mn |
| Dec 31, 2025 | -19.50 Mn |
| Sep 30, 2025 | -68.77 Mn |
| Jun 30, 2025 | -36.34 Mn |
| Mar 31, 2025 | -52.98 Mn |
| Dec 31, 2024 | -46.83 Mn |
| Sep 30, 2024 | -62.63 Mn |
| Jun 30, 2024 | -48.19 Mn |
| Mar 31, 2024 | -42.75 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -39.28 Mn |
| Jun 30, 2023 | -38.00 Mn |
| Mar 31, 2023 | -48.15 Mn |
| Dec 31, 2022 | -31.41 Mn |
| Sep 30, 2022 | 46.59 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | 230.81 Mn |
| Dec 31, 2021 | 84.71 Mn |
| Sep 30, 2021 | -24.97 Mn |
| Jun 30, 2021 | -2.07 Mn |